Micromet presented exciting data at ASH, no doubt. The only reason I didn’t mention them is lack of time.

The ALL study clears the way for a pivotal study in adult ALL, it’s a niche market but be could be a great entry ticket to market.
On the NHL front, the data continues to be robust, but there were no meaningful news. The company says it is still working on improving the safety profile and administration ( from i.v to subcutaneous).
The only bad thing I can say is that it is taking them way too long. They need a large partner, but Medimmune hasn’t been active until now. Hopefully we will hear from Medimmune soon regarding a US trial of MT103.

Ohad

Great article, as usual.
I am just a little bit surprised that you didn’t say a word about MITI. I was under the impression they presented excellent data at ASH.

Thanks,
Craig